Exploratory analyses of CSF samples revealed a trend toward reduced levels of GalCer and GlcCer in LRRK2-PD patients following DNL201 treatment, while BMP levels did not show a significant treatment response in CSF (Fig. 7E and Supplementary Fig. S7C). This evidence concerns the gene LRRK2 and Parkinson disease.